Name: PF-06463922
Price: 233.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    PF-06463922 is a potent and selective ALK/ROS1 inhibitor with IC50 values ranging from 0.19-0.53 nM for the kinase activity of ROS1 fusion enzymes [1].The receptor tyrosine kinase c-ros oncogene1 (ROS1) is a receptor with a kinase domain that is related to the anaplastic lymphoma kinase/lymphocyte-specific protein tyrosine kinase (ALK/LTK) and insulin receptor (INSR) RTK families [1]. Via cellular ROS1 autophosphorylation in the recombinant enzyme assay, PF-06463922 showed a 30-fold improved potency against ROS1, compared with crizotinib, ceritinib, alectinib and foretinib (XL-880). Engineered NIH 3T3 cells were expressing oncogenic human ROS1 fusions. In these cells, PF-06463922 was more potent than foretinib and crizotinib by >10 folds, more potent than alectinib and ceritinib by >100 folds against cellular ROS1 autophosphorylation [1].Oncogenic gene fusions involving the 3' region of ROS1 kinase had been found in various human cancers [2]. Mice bearing CD74-ROS1, CD74-ROS1G2032R and FIG-ROS1(S) s.c. Tumors (250 mm3) were used. Treatments with PF-06463992 at various doses were applied consecutively for 7 or 9 d. At dosages of 0.2 to 1 mg/kg/d, PF-06463922 significantly inhibited the growth of both established FIGROS1(S) and CD74-ROS1 tumors compared with vehicle control. At 2-6 mg/kg/d, PF-06463922 significantly made tumor volumes regress (58–85%, P < 0.0001). In animals bearing NIH 3T3-CD74-ROS1G2032R tumors, treatment with PF-06463922 at 1.0, 3.0, and 10 mg/kg/d significantly inhibited tumor growth by 28%, 44% and 90%, respectively. At 30 mg/kg/d, PF-06463922 made tumor regress by 12%, compared with vehicle [1].
    
    [1]. Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proceedings of the National Academy of Sciences, 2015, 112(11): 3493-3498.
    [2]. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non–small cell lung cancer. Clinical Cancer Research, 2012, 18(17): 4570-4579.
- Properties
  - Alternative Name
    
    lorlatinib
    
    CAS Number
    
    1454846-35-5
    
    Molecular Formula
    
    C21H19FN6O2
    
    Molecular Weight
    
    406.41
    
    Appearance
    
    A solid
    
    Purity
    
    99.22%
    
    Solubility
    
    insoluble in H2O; ≥20.3 mg/mL in DMSO; ≥5.85 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

PF-06463922

PF-06463922

Background

We Also Recommend

Abscisic Acid (Dormin)

Lomitapide

RBC8